Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells

Fig. 2

MAKV-8 inhibits HDAC activities in vitro and binds to the ligand-binding pocket of HDAC isoenzymes. (a) In vitro HDAC activity assays were conducted with increasing MAKV-8 concentrations. Relative activities of total HDAC, HDAC1, and HDAC6 were determined by comparison to the vehicle, DMSO. (b) Docking poses of MAKV-8 (stick model, orange) on the crystal structure of indicated HDAC isoenzymes (white; PDB codes: see Methods section). Numbered residues forming hydrophobic interactions in the binding sites (stick representation) correspond to HDAC1 to HDAC8 from top to bottom. Zinc atom is shown as a purple sphere; nitrogen and oxygen are colored in blue and red, respectively

Back to article page